The nation of Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) spanning five years because of the United States' demand for sensitive data.
The decision came to light following a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "unbalanced".
A government representative has since stated that the United States was requesting genetic material for research and commercial purposes while was unwilling to guarantee the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more negotiations to reach a deal agreeable to both sides so the country's vital HIV programme can continue.
Broader Context
Zimbabwe's decision comes after a similar case in Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the security of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its spending was "inefficient" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
Based on reports, 16 African countries have to date signed these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment via US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information over an extended period, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Put simply, our country would provide the raw materials for medical research without any certainty that the resulting innovations would be accessible to our population if a future health crisis emerge."
National Interest and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were upending structures previously set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This mechanism is designed to ensure that when a country contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing discussions with our US partners on how future co-operation might be arranged in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts said it recognised the government's concerns, but urged that negotiations need to persist since a large portion of the nation's Aids initiatives depended on foreign aid.
"In cases where technical issues exist, such as those relating to information security or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it commented.
The halted deal emphasises the ongoing debate between receiving vital international aid and safeguarding a country's data in an increasingly interconnected world.